drugset
drugset / Trial / NCT03744468

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

NCT03744468 ↗

Phase 1/2 Completed 147 enrolled BeiGene
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.

Timeline

Start
2018-11-13
Primary completion
2025-02-06
Completion
2025-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcestobart Monoclonal antibody 300 mg Intravenous
Subject Alcestobart Monoclonal antibody 600 mg Intravenous
Subject Alcestobart Monoclonal antibody 900 mg Intravenous
Subject Alcestobart Monoclonal antibody 1200 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 2 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 6 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 20 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 60 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 200 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 400 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 600 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 800 mg Intravenous
Subject Surzebiclimab Monoclonal antibody 1600 mg Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma